PEN
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
Penumbra, Inc. (PEN) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Value (D+). The rating has held at C for 3 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | D+ (1.6) | C (2.3) | B+ (3.6) | B- (3.1) | D+ (1.6) | C (2.4) |
| 2026-11-09 | D (1.5) | C (2.3) | B+ (3.6) | B- (3.1) | D+ (1.6) | C (2.4) |
| 2026-11-02 | D+ (1.5) | C (2.3) | B+ (3.6) | B- (3.0) | D+ (1.6) | C (2.4) |
| 2026-11-01 | D+ (1.6) | C (2.2) | B+ (3.6) | C+ (2.8) | D+ (1.7) | C (2.4) |
| 2026-10-26 | D+ (1.6) | C (2.2) | B+ (3.6) | C+ (2.8) | C- (2.1) | C (2.5) |